Project Grant R36AG088233
Award Date 8/1/24
Completion Date 7/31/25
Dollars Obligated $208K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...
- The National Institute on Aging awarded a $6.72 million Project Grant to the University of Pennsylvania, with an award date of September 15, 2025 and completion date of August 31, 2029, under the Aging Research program (CFDA 93.866). This project, titled "Defining Short RNA Therapeutics That Combat TDP-43 Proteinopathy Connected to AD and ADRDs," will develop and advance short RNA-based therapeutic candidates designed to prevent and reverse aberrant phase separation of TDP-43 (TAR...
- The Project Grant award of $404,058 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research to identify novel small molecules that stabilize functional, multimeric forms of the TDP43 protein. The goal is to restore TDP43's native RNA binding and splicing regulation functions, which are impaired in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other TDP43-related neurodegenerative diseases. The research will leverage high-throughput...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Advantage Therapeutics, Inc. a Project Grant of $1,249,957 (awarded September 20, 2025) under the Aging Research program (CFDA 93.866) to conduct preclinical and Investigational New Drug (IND)-enabling studies on a novel small-molecule disease-modifying therapeutic for Alzheimer's disease. The proposed treatment is designed to reduce brain inflammation and restore phagocytosis, thereby improving amyloid...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,853,477 to the Research Foundation for Mental Hygiene, Inc. (RFMH) at the Nathan S. Kline Institute to conduct research on hyperexcitability and interictal spike activity in Alzheimer's disease. The research aims to investigate the origins and mechanisms of these neural phenomena, as well as evaluate whether selectively inhibiting them can improve cognition and reduce...
- Federal Project Grant Award Summary Reelin Therapeutics, Inc. received a $258,213 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective September 20, 2025, with completion targeted for May 31, 2027. The award funds research and development activities focused on identifying next-generation gamma-secretase modulators (GSMs) for Alzheimer's disease treatment. The company will conduct medicinal chemistry, ligand and structure-based drug...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...
- Summary This Cooperative Agreement, awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), funds UC San Diego to conduct in vitro pharmacology, chronic toxicology, and embryo-fetal development studies to demonstrate the safety profile of GSM-779690, a small molecule G-secretase modulator (GSM) candidate therapeutic for Alzheimer's disease. The award totals $3,225,280 and runs from August 15, 2025, through July 31, 2027. The research aims to support...
- Federal Cooperative Agreement Summary Award: Design and Development of Glutamate Transporter Activators for Disease-Modifying and Symptomatic Treatment of Epilepsy Funding Agency: National Institute of Neurological Disorders and Stroke (NINDS) Federal Grant Program: Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) Award Amount: $576,788 | Award Date: March 15, 2026 | Completion Date: February 28, 2027 Drexel University will conduct translational research...